ULTRAGENYX PHARMACEUTICAL INC. Payments to Acquire Debt Securities, Available-for-sale
ULTRAGENYX PHARMACEUTICAL INC. (RARE) reported Payments to Acquire Debt Securities, Available-for-sale of $188.00 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Cash Flow › Investing Activities
us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt · last filed 2026-08-05
- ULTRAGENYX PHARMACEUTICAL INC. payments to acquire debt securities, available-for-sale for the quarter ending 2026-06-30 was $57.00M, a 256.25% increase year-over-year.
- ULTRAGENYX PHARMACEUTICAL INC. payments to acquire debt securities, available-for-sale for the quarter ending 2026-03-31 was $131.00M.
- ULTRAGENYX PHARMACEUTICAL INC. payments to acquire debt securities, available-for-sale for the quarter ending 2025-12-31 was $153.56M, a 840.90% increase year-over-year.
- ULTRAGENYX PHARMACEUTICAL INC. payments to acquire debt securities, available-for-sale for the quarter ending 2025-09-30 was $16.45M, a 95.52% decline year-over-year.
- ULTRAGENYX PHARMACEUTICAL INC. payments to acquire debt securities, available-for-sale for fiscal 2025 was $186.00M, a 54.52% decline from fiscal 2024.
- ULTRAGENYX PHARMACEUTICAL INC. payments to acquire debt securities, available-for-sale for fiscal 2024 was $409.00M, a 22.24% decline from fiscal 2023.
- ULTRAGENYX PHARMACEUTICAL INC. payments to acquire debt securities, available-for-sale for fiscal 2023 was $526.00M, a 14.43% decline from fiscal 2022.
- ULTRAGENYX PHARMACEUTICAL INC. payments to acquire debt securities, available-for-sale for fiscal 2022 was $614.74M, a 39.27% decline from fiscal 2021.
| Period end | Payments to Acquire Debt Securities, Available-for-sale 3 month | Payments to Acquire Debt Securities, Available-for-sale 6 month | Payments to Acquire Debt Securities, Available-for-sale 6 month as first filed | Payments to Acquire Debt Securities, Available-for-sale 9 month | Payments to Acquire Debt Securities, Available-for-sale 12 month | Payments to Acquire Debt Securities, Available-for-sale 12 month as first filed |
|---|---|---|---|---|---|---|
| 2026-06-30 | $57.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-05 | $188.00M 10-Q · filed 2026-08-05 | $341.56M derived: sum of 3 quarters · filed 2026-08-05 | $358.00M derived: sum of 4 quarters · filed 2026-08-05 | ||
| 2026-03-31 | $131.00M 10-Q · filed 2026-05-06 | $284.56M derived: sum of 2 quarters · filed 2026-05-06 | $301.00M derived: sum of 3 quarters · filed 2026-05-06 | $317.00M derived: sum of 4 quarters · filed 2026-08-05 | ||
| 2025-12-31 | $153.56M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-18 | $170.00M derived: sum of 2 quarters · filed 2026-02-18 | $186.00M derived: sum of 3 quarters · filed 2026-08-05 | $186.00M 10-K · filed 2026-02-18 | ||
| 2025-09-30 | $16.45M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-05 | $32.45M derived: sum of 2 quarters · filed 2026-08-05 | $32.45M 10-Q · filed 2025-11-05 | $48.77M derived: sum of 4 quarters · filed 2026-08-05 | ||
| 2025-06-30 | $16.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-05 | $16.00M 10-Q · filed 2026-08-05 | $15.50M 10-Q · filed 2025-08-06 | $32.32M derived: sum of 3 quarters · filed 2026-08-05 | $399.70M derived: sum of 4 quarters · filed 2026-08-05 | |
| 2025-03-31 | $0.00 10-Q · filed 2026-05-06 | $16.32M derived: sum of 2 quarters · filed 2026-05-06 | $383.70M derived: sum of 3 quarters · filed 2026-05-06 | $387.07M derived: sum of 4 quarters · filed 2026-05-06 | ||
| 2024-12-31 | $16.32M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-18 | $383.70M derived: sum of 2 quarters · filed 2026-02-18 | $387.07M derived: sum of 3 quarters · filed 2026-02-18 | $409.00M 10-K · filed 2026-02-18 | $408.61M 10-K · filed 2025-02-19 | |
| 2024-09-30 | $367.38M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-05 | $370.75M derived: sum of 2 quarters · filed 2025-11-05 | $392.68M 10-Q · filed 2025-11-05 | $613.89M derived: sum of 4 quarters · filed 2026-02-18 | ||
| 2024-06-30 | $3.37M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-06 | $25.30M 10-Q · filed 2025-08-06 | $246.51M derived: sum of 3 quarters · filed 2026-02-18 | $386.00M derived: sum of 4 quarters · filed 2026-02-18 | ||
| 2024-03-31 | $21.93M 10-Q · filed 2025-05-07 | $243.14M derived: sum of 2 quarters · filed 2026-02-18 | $382.62M derived: sum of 3 quarters · filed 2026-02-18 | $485.90M derived: sum of 4 quarters · filed 2026-02-18 | ||
| 2023-12-31 | $221.21M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-18 | $360.69M derived: sum of 2 quarters · filed 2026-02-18 | $463.98M derived: sum of 3 quarters · filed 2026-02-18 | $526.00M 10-K · filed 2026-02-18 | $526.38M 10-K · filed 2024-02-21 | |
| 2023-09-30 | $139.48M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-06 | $242.76M derived: sum of 2 quarters · filed 2024-11-06 | $304.79M 10-Q · filed 2024-11-06 | $503.36M derived: sum of 4 quarters · filed 2025-02-19 | ||
| 2023-06-30 | $103.28M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-02 | $165.31M 10-Q · filed 2024-08-02 | $363.88M derived: sum of 3 quarters · filed 2025-02-19 | $574.76M derived: sum of 4 quarters · filed 2025-02-19 | ||
| 2023-03-31 | $62.02M 10-Q · filed 2024-05-03 | $260.60M derived: sum of 2 quarters · filed 2025-02-19 | $471.48M derived: sum of 3 quarters · filed 2025-02-19 | $473.05M derived: sum of 4 quarters · filed 2025-02-19 | ||
| 2022-12-31 | $198.57M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-19 | $409.46M derived: sum of 2 quarters · filed 2025-02-19 | $411.02M derived: sum of 3 quarters · filed 2025-02-19 | $614.74M 10-K · filed 2025-02-19 | ||
| 2022-09-30 | $210.88M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-03 | $212.45M derived: sum of 2 quarters · filed 2023-11-03 | $416.16M 10-Q · filed 2023-11-03 | $510.94M derived: sum of 4 quarters · filed 2024-02-21 | ||
| 2022-06-30 | $1.57M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-04 | $205.28M 10-Q · filed 2023-08-04 | $300.06M derived: sum of 3 quarters · filed 2024-02-21 | $553.12M derived: sum of 4 quarters · filed 2024-02-21 | ||
| 2022-03-31 | $203.71M 10-Q · filed 2023-05-05 | $298.49M derived: sum of 2 quarters · filed 2024-02-21 | $551.55M derived: sum of 3 quarters · filed 2024-02-21 | $810.67M derived: sum of 4 quarters · filed 2024-02-21 | ||
| 2021-12-31 | $94.78M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-21 | $347.84M derived: sum of 2 quarters · filed 2024-02-21 | $606.96M derived: sum of 3 quarters · filed 2024-02-21 | $1.01B 10-K · filed 2024-02-21 | ||
| 2021-09-30 | $253.06M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-03 | $512.18M derived: sum of 2 quarters · filed 2022-11-03 | $917.41M 10-Q · filed 2022-11-03 | $1.08B derived: sum of 4 quarters · filed 2023-02-17 | ||
| 2021-06-30 | $259.12M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-07-29 | $664.35M 10-Q · filed 2022-07-29 | $829.06M derived: sum of 3 quarters · filed 2023-02-17 | $1.02B derived: sum of 4 quarters · filed 2023-02-17 | ||
| 2021-03-31 | $405.23M 10-Q · filed 2022-05-06 | $569.94M derived: sum of 2 quarters · filed 2023-02-17 | $762.14M derived: sum of 3 quarters · filed 2023-02-17 | $933.24M derived: sum of 4 quarters · filed 2023-02-17 | ||
| 2020-12-31 | $164.71M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-17 | $356.91M derived: sum of 2 quarters · filed 2023-02-17 | $528.01M derived: sum of 3 quarters · filed 2023-02-17 | $813.24M 10-K · filed 2023-02-17 | ||
| 2020-09-30 | $192.19M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-03 | $363.30M derived: sum of 2 quarters · filed 2021-11-03 | $648.52M 10-Q · filed 2021-11-03 | |||
| 2020-06-30 | $171.10M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-03 | $456.33M 10-Q · filed 2021-08-03 | ||||
| 2020-03-31 | $285.23M 10-Q · filed 2021-05-05 | |||||
| 2019-12-31 | $692.82M 10-K · filed 2022-02-15 | |||||
| 2018-12-31 | $509.80M 10-K · filed 2021-02-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| OMEROS CORP (OMER) | United States | $1.456B | 5.50 |
| ArriVent BioPharma, Inc. (AVBP) | United States | $1.485B | -10.25 |
| Innoviva, Inc. (INVA) | United States | $1.493B | 4.62 |
| Oric Pharmaceuticals, Inc. (ORIC) | United States | $1.367B | -8.00 |
| ANAPTYSBIO, INC (ANAB) | United States | $1.546B | -60.20 |
| Kailera Therapeutics, Inc. (KLRA) | United States | $1.552B | |
| Kardigan, Inc. (KARD) | United States | $1.346B | |
| Tyra Biosciences, Inc. (TYRA) | United States | $1.337B | -12.83 |
| Bicara Therapeutics Inc. (BCAX) | United States | $1.309B | -10.55 |
| Syndax Pharmaceuticals Inc (SNDX) | United States | $1.606B | -8.82 |